Otitis Media - Pipeline Review, H2 2019

Global Markets Direct’s, ‘Otitis Media - Pipeline Review, H2 2019’, provides an overview of the Otitis Media pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Otitis Media, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Otitis Media

- The report reviews pipeline therapeutics for Otitis Media by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Otitis Media therapeutics and enlists all their major and minor projects

- The report assesses Otitis Media therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Otitis Media

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Otitis Media

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Otitis Media pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Lee's Pharmaceutical Holdings Ltd

Madam Therapeutics BV

Merck & Co Inc

MerLion Pharmaceuticals Pte Ltd

Novus Therapeutics Inc

Yuhan Corp

Lee's Pharmaceutical Holdings Ltd

Madam Therapeutics BV

Merck & Co Inc

MerLion Pharmaceuticals Pte Ltd

Novus Therapeutics Inc

Yuhan Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Otitis Media – Overview

Otitis Media – Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Otitis Media – Overview

Otitis Media – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Otitis Media – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Otitis Media – Companies Involved in Therapeutics Development

Lee's Pharmaceutical Holdings Ltd

Madam Therapeutics BV

Merck & Co Inc

MerLion Pharmaceuticals Pte Ltd

Novus Therapeutics Inc

Yuhan Corp

Otitis Media – Drug Profiles

(cholesteryl palmitate + colfosceril palmitate) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(dexamethasone + piperacillin + tazobactam) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aspoxicillin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Otitis Media – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENT-103 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

finafloxacin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OR-404IT – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pazufloxacin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PCL-1440 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pneumococcal (13-valent) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pneumococcal (23-valent) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Otitis Media – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tebipenem pivoxil – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Otitis Media – Dormant Projects

Otitis Media – Product Development Milestones

Featured News & Press Releases

Jun 10, 2019: Novus Therapeutics to present OP0201 data at the 20th international symposium on recent advances in otitis media

Apr 23, 2019: Novus’ Phase I trials of otitis media drug meet primary objective

Feb 20, 2019: Novus Therapeutics begins dosing in otitis media drug trial

Feb 11, 2019: Novus Therapeutics doses first subjects in phase 1 pharmacodynamics study of OP0201

Jan 30, 2019: Novus Therapeutics Advances OP0201 Development Program Across Several Clinical Trials

Jan 10, 2019: Novus doses first patient in Phase I trial of OP0201

Dec 04, 2018: Novus Therapeutics announces formation of Scientific Advisory Board

Nov 28, 2018: Novus Therapeutics doses first subject in Phase I trial of OP0201

Jun 19, 2018: Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis Media

Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra’s Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media

Oct 29, 2012: Study Suggests New Way to Prevent Recurrent Ear Infections

Apr 18, 2012: MerLion Initiates Phase III Clinical Program To Evaluate Finafloxacin For Treatment Of Acute Otitis Media

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Otitis Media, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products ...

List of Tables

Number of Products under Development for Otitis Media, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Otitis Media – Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2019

Otitis Media – Pipeline by Madam Therapeutics BV, H2 2019

Otitis Media – Pipeline by Merck & Co Inc, H2 2019

Otitis Media – Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2019

Otitis Media – Pipeline by Novus Therapeutics Inc, H2 2019

Otitis Media – Pipeline by Yuhan Corp, H2 2019

Otitis Media – Dormant Projects, H2 2019

List of Figures

List of Figures

Number of Products under Development for Otitis Media, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products ...

List of Figures

Number of Products under Development for Otitis Media, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports